Loading clinical trials...

A Study of LY4060874 in Healthy Participants | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITINGPHASE1

A Study of LY4060874 in Healthy Participants

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY4060874 in Healthy Participants

NCT06709820•Eli Lilly and Company

Summary

The purpose of this study is to evaluate safety and tolerability of LY4060874 in healthy participants. Study participation may last up to 22 weeks and up to approximately 18 study visits.

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Are overtly healthy as determined by medical evaluation, including medical history and physical examination.
•Have a body mass index in the range of 20 to 29.9 kilogram per meter squared (kg/m²), inclusive, at screening.
•To qualify as Chinese for this study, all 4 of the participant's biological grandparents must be of exclusive Chinese descent and born in China.
•To qualify as a participant of first-generation Japanese origin, the participant, the participant's biological parents, and all the participants' biological grandparents must be of exclusive Japanese descent and born in Japan.

Exclusion Criteria

•Have a history of or have been diagnosed with Type 1 or Type 2 diabetes mellitus.
•Have hemoglobin A1c (HbA1c) \> 6.4% or 46 millimoles/mole (mmol/mol) at screening.
•Have taken approved, including over the counter (OTC) or prescribed, medication or investigational medication for weight loss, including GLP-1 receptor agonists, within the previous 3 months of study screening.
•Have had surgical treatment for obesity.
•Are actively participating in a weight loss program or intend to initiate an intensive diet and/or exercise program during the study.

Locations (2)

Fortrea, Inc.

Dallas, Texas, United States

Lilly Centre for Clinical Pharmacology

Singapore, Singapore

Key Dates

Start Date

December 2, 2024

Primary Completion Date

March 1, 2026

Completion Date

March 1, 2026

Last Updated

March 3, 2026

Enrollment

132

ESTIMATED participants

Conditions

Healthy Participants

Interventions

LY4060874

DRUG

LY4060874

DRUG

Placebo

DRUG

Placebo

DRUG

A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity

NCT07310901

Obese But Otherwise Healthy Participants

View study

RECRUITINGPHASE1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases

NCT06342713

Healthy ParticipantsHealthy Subjects+5 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 3, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study of LY4060874 in Healthy Participants

Inclusion Criteria

Exclusion Criteria

A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases

Study of BW-50218 in Healthy Participants

A Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SYH2085

A Phase I/II, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a Broadly Protective Sarbecovirus Vaccine (GBP511) in Healthy Adults.

A Study to Evaluate Single and Multiple Doses of TLC-1180 in Healthy Subjects